Key result
Early loop-diuretic use in hospitalized heart failure is linked to ~31% higher risk of kidney deterioration.
Why the study?
Early loop diuretics are central to decongestion in heart failure, but their association with subsequent kidney deterioration remains uncertain.
Does early loop-diuretic administration within 6 hours increase the risk of subsequent kidney deterioration in hospitalized adults with heart failure?
Cohort (n=15,764)
Does early loop-diuretic administration within 6 hours increase the risk of subsequent kidney deterioration in hospitalized adults with heart failure?
Although early loop-diuretic administration within 6 hours of admission was associated with higher subsequent creatinine-defined kidney deterioration in hospitalized heart failure patients, attenuation of this effect when accounting for monitoring intensity suggests differential surveillance and confounding by indication rather than true harm.
Answers are grounded in this paper and cite their sources.
Warrants caution interpreting early diuretic timing; leaves open confounding by indication or surveillance in this observational analysis.
Early loop diuretics are central to decongestion in heart failure, but their association with subsequent kidney deterioration remains uncertain. We conducted a retrospective 6-hour landmark study of adults with ICD-coded heart failure in MIMIC-IV. Exposure was documented administration of furosemide, bumetanide, or torsemide before 6 hours. Eligible admissions required baseline creatinine and a follow-up measurement from 6 to <48 hours. Kidney deterioration was defined as a creatinine increase of ≥0.3 mg/dL or ≥1.5-fold from baseline. We estimated crude and adjusted associations using propensity-score weighting and augmented inverse probability weighting (AIPW); adjusted and weighted confidence intervals accounted for repeated admissions by patient, whereas the crude interval did not. Among 23,336 admissions from 15,764 patients, 2,453 (10.5%) received early treatment and 4,506 (19.3%) met the endpoint. Kidney deterioration occurred in 22.7% of early-treated admissions versus 18.9% of comparators (crude risk ratio [RR] 1.20, 95% CI 1.11–1.30). The directly adjusted RR was 1.30 (95% CI 1.20–1.41), the overlap-weighted RR was 1.31 (95% CI 1.21–1.43), and the AIPW RR was 1.31 (95% CI 1.20–1.44). The overlap-weighted absolute risk difference was 5.5 percentage points (95% CI 3.7–7.4). Mortality was not significantly associated with early treatment (RR 1.12, 95% CI 0.96–1.30). Restricting the endpoint to the first follow-up creatinine attenuated the association (overlap-weighted RR 1.01, 95% CI 0.87–1.17), highlighting sensitivity to monitoring intensity. Early loop-diuretic administration was associated with higher subsequent creatinine-defined deterioration, but differential surveillance and confounding by indication preclude causal conclusions or recommendations to delay treatment.
No takes yet. Share an insight, caveat, or question.
Mrayyan et al. (2026) conducted a cohort in Heart failure (n=15,764). Early loop-diuretic administration (furosemide, bumetanide, or torsemide before 6 hours) vs. No loop-diuretic administration before 6 hours was evaluated on Kidney deterioration (creatinine increase of ≥0.3 mg/dL or ≥1.5-fold from baseline) (RR 1.31, 95% CI 1.21-1.43). Early loop-diuretic administration (<6 hours) in hospitalized heart failure was associated with higher kidney deterioration vs comparators.
Synapse has enriched 10 related papers. Consider them for comparative context: